Introduction
Hematopoietic stem cells (HSCs) that are used in clinical transplantation are derived from bone marrow, peripheral blood or from umbilical cord blood. 1 Unfortunately, harsh preconditioning regimens, drug toxicity and the requirement for immunosuppression preclude routine application of these HSCs in the treatment of devastating hematopoietic malignancies. In addition, approximately two-thirds of transplantation patients lack suitable HLA-matched donors. Those patients who find donors face the burden of non-specific immunosuppression, increased risk of opportunistic infections, and the potential development of secondary malignancies. 2, 3 However, pluripotent stem cells have recently emerged as an alternative source of cells that can be used in regenerative medicine. [4] [5] [6] Moreover, several groups have reported that ESCs are poorly immunogenic due to their low expression of classical major histocompatibility complex (MHC)-I and lack of MHC-II antigens. 7, 8 Our group recently successfully established mixed chimerism in mice transplanted with mouse ES cell-derived HPCs 7 and for the first time showed that HPC-established mixed chimerism induced transplantation tolerance to cardiac allografts. 9 Moreover, unlike adult stem cells, hESCs and their derivatives are not susceptible to immunological rejection. 8 However, the use of hESCs for the treatment of diseases is complicated by the limited number of available hES cell lines. Furthermore, hESCs remain ethically and morally controversial. Thus, an alternative source of pluripotent stem cells is most desirable.
Recently, Yamanaka and colleagues established induced pluripotent stem cells (iPSCs) by reprogramming fibroblasts into a pluripotent state by means of retroviral transduction of four factors: Oct 3/4, Sox2, Klf4 and c-Myc. 10 Even though iPSCs are
For personal use only. on October 31, 2017 . by guest www.bloodjournal.org From similar to ESCs in their morphology, expression of pluripotent stem cell genes, ability to form embryoid bodies (EB) and possess the unique potential to differentiate into lineage committed cells, recent molecular studies show genetic and molecular differences between both forms of pluripotent stem cells, 11 which might affect their differentiation into lineage committed cells. One caveat that remains to be resolved is avoidance of viral vectors during the reprogramming process. These retro-viral vectors can induce epigenetic changes which can lead to tumor formation but also affect their potential to differentiate. Interestingly, several alternative methods for the generation of iPSCs have now been reported, including the use of only two reprogramming factors or the use of plasmids, recombinant proteins, mRNA and miRNA-mediated reprogramming. [12] [13] [14] [15] [16] [17] [18] These new procedures, however, remain very inefficient. The use of small molecules in combination with reprogramming transcription factors is a further alternative approach in generating human iPSCs. 19 Lastly, in addition to fibroblasts, many other cell types have been successfully used to generate iPSCs, [20] [21] [22] [23] In this study, we show that iPS cell-derived CD34 + iPS-HPCs poorly express classical MHC antigens, lack CD80 and CD86 and highly express the T-cell inhibitory ligand PD-L1. Our data show that these HPC characteristics induce T-cell anergy in alloreactive T-cells, which can be exploited for allogenic transplantation of iPS cellderived progenitor cells.
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Methods

Cell lines
Human iPSCs reprogrammed from fibroblasts of patients with mucopolysaccharidosis type VI (CHOPWT3.1) and from fibroblasts of apparently healthy non-fetal tissue (CHOPWT2.2) were purchased from the Children's Hospital of Philadelphia, Center for Cellular and Molecular Therapeutics, hESC/iPSC Core Facility. Other iPSCs, GM23226
(IDDM) and GM23262 (BMD) were purchased from Coriell Institute for Medical
Research. We also generated iPSCs from MRC5 (Fibroblasts, ATCC) ( Figure S1 ).
Human iPSCs and ESCs (H13, from Wicell) were cultured in DMEM/F12 medium supplemented with 20% Knockout Serum (GIBCO/BRL), 10ng/ml bFGF, 1mM GlutaMax, 50U/ml penicillin and 50μg/ml streptomycin, 1X nonessential amino acids and 100µM 2-mercaptoethanol (Invitrogen). CTLs, immortalized B-cells and PBMCs were cultured in complete RPMI medium.
Cytotoxicity assay
HLA-A2 specific CTLs were generated as we previously described. 27 Briefly, we cocultured PBMCs with irradiated immortalized B-cells (HLA*A2/3, B7, Cw7) for 7 days.
Consequently, CTLs were restimulated every 7-10 days 2 times, then re-stimulated with HSB-2 (HLA*A1/2, B44/w57, Cw1/3) for 7 days. After this re-stimulation, HLA-A2-specific CTLs were re-stimulated with immortalized B-cells every 7 days in complete RPMI-1640 medium supplemented with rIL-2. These CTLs were used as effector cells while iPS-HPCs, M23e immortalized B-cells and M28e cells were used as target cells in 4h 51 Cr-release assay, as described previously.
25
IFN-γ treatment
To upregulate expression of MHC-I, iPS-HPCs were treated with rhIFN-γ (50ng/ml, PeproTech) for 48h. MHC-I upregulation was confirmed through Flow Cytometry with a PE-conjugated HLA-ABC antibody. Cytotoxicity and ELISPOT assays using IFN-γ treated iPS-HPCs were performed as described above.
Statistical analysis
All of the experiments were performed at least 3 times in order to achieve statistically significant results (p<0.05). GraphPad Prism 5 Statistics Software was used for statistical evaluation.
Results
Human iPSCs differentiate into hematopoietic progenitor cells (HPCs)
iPSCs were generated from commercially available fibroblasts using the Yamanaka factors Oct4, Sox2, Klf4 and c-Myc cloned into pMIG-GFP retroviral vectors ( Figure   S1A ). Our generated iPSCs had normal karyotypes and were positive for human pluripotent stem cell markers ( Figure S1B and Figure S1C ). More importantly, the cells formed EBs that expressed genes of all three germ layers ( Figure S1D ). The cell line 4F-2 generated in our lab is representative of our iPS cell lines was used in the following experiments. Table S1 shows that the DNA Short Tandem Repeats (STR) profile for the iPSCs was identical to that of the parental fibroblasts. Lastly, to more definitively establish iPS cell pluripotency, cells were injected into NOD-Scid IL2Rγ null mice to determine teratoma formation. These mice developed teratomas after 9 to 12 weeks. H&E staining of the teratomas revealed tissues of all three germ layers ( Figure   S1E ). These data altogether show that we successfully generated pluripotent iPSCs from fibroblasts.
Next, we differentiated iPSCs into CD34 + HPCs and studied their immunological characteristics. iPSCs were differentiated using a modified protocol. 28, 29 To determine the phenotype of iPS-HPCs, the differentiated cells were isolated using 0.05% trypsin and stained with various antibodies directed against hematopoietic cell markers ( Figure   1A ). On day 9 of the differentiation process, HPCs expressed CD34 (17%), the erythroid cell marker CD235a (8.61%), CD34/CD43 (5.9%) and CD34/CD45 (3.3%). These results are summarized in Figure 1B . In addition, HPCs were generated from four additional iPS cell lines either purchased or kindly provided by other investigators. As depicted in Figure 1C , the yield of CD43 + /CD34 + HPCs varied among these five different iPS cell lines, suggesting possible epigenetic and molecular differences between the iPS cell lines. Furthermore, to confirm that the iPS-HPCs were indeed hematopoietic cells, RT-PCR was performed for the hematopoietic genes HoxA9, GATA-1, CD41 and CD45 ( Figure 1D ). Undifferentiated iPSCs and CD34 + cells from umbilical cord blood (UCB) were used as controls. Additionally, iPS-HPCs uniformly expressed the hematopoietic stem cell marker CD90, similar to UCB-CD34 + cells ( Figure S2 ). CD33, which is expressed by lineage committed cells 30 , was not expressed by iPS-HPCs but was found on the majority of UCB-CD34 + cells ( Figure S2 Table S2 .
To further determine the hematopoietic potential of the iPS-HPCs, colony forming units (CFUs) were studied. Human iPS-HPCs were able to generate multi-lineage hematopoietic cells, namely CFU-E, -GEMM, -M, -GM and -G, Figure 2A . The relative percentages of these lineage committed cells are summarized in Figure 2B , showing that the iPS-HPCs were capable of multi-lineage differentiation.
iPS-HPCs poorly express HLA molecules
Our goal here was to determine the immunological characteristics of iPS-HPCs, in Here, we studied the MHC expression by iPS-HPCs, iPSCs and the parental fibroblasts. ESCs, ESC-HPCs, and UCB-CD34 + cells were included as controls.
Interestingly, MHC expression by iPSCs was less than that by fibroblasts and by UCB-CD34 + cells ( Figure 3 ). This is consistent with our own studies on rat embryonic-like stem cells which poorly expressed MHC 31 and is now a well-established characteristic of ESC-HPCs. 7, 32 Further, iPS-HPCs expressed the non-classical MHC molecules HLA-G and HLA-E ( Figure 3 and Table S3 ), albeit at modest levels. Additionally, HLA-G expression varied among the iPS cell lines used (Table S3) . Interestingly, treatment of HPCs with IFN-γ enhanced their expression of HLA-E but not HLA-G ( Figure S4 ). Lastly, iPS-HPCs slightly expressed MIC-A/B, ligands for NK cell activating receptors (Table   S3 ). In addition, iPS-HPCs remained negative for MHC-II molecules, an observation that is consistent with our prior studies on mouse ESC-HPCs. In contrast, UCB-CD34 + cells highly expressed MHC-I but had poor expression of MHC-II antigens.
iPS-HPCs do not stimulate HLA-A2 specific CTLs
We and others previously reported that mouse ESCs and ES cell-derivatives are poorly immunogenic. 32, 33 To determine whether low MHC-I expression influenced the susceptibility of iPS-HPCs toward alloreactive T-cell killing, we established HLA-A2
specific CTLs as we previously described. 27 After 5 weeks in culture, 85% of the CTLs were CD8 + ( Figure 4A ). CTL cytotoxicity was tested using a 4h 51 Cr-release assay. The
CTLs strongly killed HLA-A2 target cells in a 4h 51 Cr-release assay, but surprisingly failed to kill iPS-HPCs ( Figure 4B ). Similarly, third-party target cells that did not express HLA-A2 were not lysed. To determine whether iPS-HPCs activate CTLs, we used the ELISPOT assay to measure IL-2 secretion by CTLs in response to stimulator cells at different time points. We observed robust IL-2 secretion by CTLs cultured with immortalized B-cells (HLA-A2) but not by CTLs cultured with either HPCs or with thirdparty control ( Figure 4C ). Altogether, our data demonstrate that iPS-HPCs failed to stimulate the HLA-A2 specific CTLs despite their expression of HLA-A2, suggesting that these cells poorly engage with HLA-A2 specific TCRs.
We speculated that lack of CTL activation by HPCs was due to poor MHC expression. Here, to determine whether upregulation of MHC-I molecules in the iPSHPCs enhances their lysis by CTLs, HPCs were stimulated with IFN-γ for 48h.
Upregulation of MHC-I antigens was confirmed by flow cytometry ( Figure 4D ). These cells were subsequently used as target cells of alloreactive CTLs. As expected, the iPSHPCs were now modestly susceptible to CTL killing ( Figure 4E ). These results were of interest as they suggested that the iPS-HPCs were protected from CTL killing due to low MHC expression.
IFN-γ treatment and CD28 costimulation enhance HPC stimulation of CTLs
Interaction of B7 family proteins with CD28 is a requirement for T-cell stimulation in concert with TCR engagement. PD-L1 (also called B7-H1, CD274) and PD-L2 (also known as B7-DC, CD273) interact with PD-1 (Programmed cell death 1). PD-1 is an inhibitory receptor expressed on T-cells, NK cells, B-cells and activated monocytes. 34, 35 Engagement of PD-1 with PD-L1 leads to the inhibition of TCR-mediated lymphocyte proliferation and cytokine secretion. 36 PD-1 is significant for the induction of peripheral CD8 + T-cell tolerance by resting DCs in vivo. 35 Furthermore, infection with the helminthes, Schistosoma mansoni or T. crassiceps upregulates the expression of PD-L1 on activated macrophages, which acquire immunosuppressive activity and induce Tcell anergy. 35, 37 The extent of costimulatory molecule expression on iPS-HPCs was determined using flow cytometry. iPS-HPCs do not express CD80, CD86 or PD-L2, but considerable levels of PD-L1, which engages PD-1, suppressing the proliferation of CD8 + T-cells, 38 ( Figure 5A ). Interestingly, expression of the costimulatory molecules was not affected by treatment with IFN-γ ( Figure 5B ).
To verify that poor MHC-I expression and lack of costimulation of iPS-HPCs induced T-cell anergy, ELISPOT assays for both IFN-γ and IL-2 were performed. As depicted in Figure 5C , IFN-γ secretion by CTLs cultured with iPS-HPCs was at a basal level when treated with an isotype control antibody or by an anti-CD28 antibody alone.
In contrast, CTLs cultured with IFN-γ treated HPCs, secreted 50 times more IFN-γ than controls. This effect was further significantly enhanced when CD28 co-stimulation ( Figure 5C ) was provided. This increased CTL response is due to the enhanced MHC-I expression and signal 2 (delivered through the anti-CD28 antibody). This effect was reciprocated when we measured IL-2 release by the CTLs, Figure 5D . Thus, lack of positive costimulatory molecules on the HPCs mediated lack of T-cell activation.
iPS-HPCs induce anergy of CD8 + T-cells
Human CD34 + stem cells have been reported to present antigen to T-cells, 39 leading to T-cell stimulation. 40 It is this characteristic which forms a formidable barrier to successful bone marrow transplantation. Since we did not observe lysis of the iPS- We previously discussed that iPS-HPCs express low levels of HLA-E and HLA-G ( Figure 3 and Table S3 ) and that IFN-γ treatment had an impact on the expression of HLA-E but not HLA-G ( Figure S4 ). This raised the question of whether these nonclassical MHC molecules played a role in the induction of T-cell anergy by iPS-HPCs. Additionally, this group showed that the genetic expression of TAP-1, TAP-2 and
Tapasin molecules was weak in ES and iPSCs. Tapasin stabilizes the TAP-1/2 complex and is involved in peptide loading of MHC-I onto the cell surface. They suggested that the absence of tapasin expression in undifferentiated human ESCs may be due to the presence of the repression marker H3K9me3. 45 During the reprogramming process and conversion of fibroblasts into iPSCs, epigenetic modifications, such as hypermethylation of DNA promoter regions, and histone modifications, have been observed. 46 Earlier studies by Ladhoff et al. showed that ESCs poorly expressed MHC-II molecules due to lack of expression of the MHC-II transcription factor CIITA. 47 Thus, poor expression of MHC antigens is an inherent characteristic of embryonic tissues since they have not yet upregulated transcription factors of the MHC complex.
After the differentiation of iPSCs into HPCs, these progenitors express HLA-G and MIC-A/B (Figure 3 and Table S3 ). HLA-G is a ligand for an NK cell inhibitory receptor, whereas MIC-A/B is a ligand for NKG2D, which is an NK cell activating receptor. 48 Thus, we consider that iPS-HPCs have the potential to activate NK cells. However, an elusive balance of inhibitory and activating signals to NK cells determines whether the target cell is killed, and thus it remains to be seen whether iPS-HPCs are actually susceptible to NK cell cytotoxicity. However, Figure S3 provides evidence that iPS-HPCs are not susceptible to NK cell killing in vitro. This is consistent with our own data using mouse
HPCs. 25 Additionally, iPS-HPCs, similar to UCB-CD34 + HPCs, do not express ULBP-1,2,5,6, which are ligands of the NK cell activating receptor NKG2D ( Figure S2 ). This evidence is consistent with data from the in vitro cytotoxicity assay ( Figure S3) indicating that iPS-HPCs are not susceptible to NK cells.
Our data show that we successfully derived CD34 + HPCs from human iPSCs and that the cells express hematopoietic genes similar to those expressed by UCB-CD34 Although iPSCs may be rejected even in autologous transplants, we show that iPSHPCs may be protected from T-cell mediated rejection due to their ability to induce Tcell anergy. We propose that poor recognition of iPS-HPCs is due to their low expression of classical MHC molecules. However, iPSCs express high levels of Oct4, which has been suggested to contribute to T-cell responses to iPSCs. 53 It will therefore be beneficial to design new reprogramming approaches that reduce Oct4 expression.
Human iPS-HPCs are very similar to ESC-HPCs in many respects, including poor expression of MHC-I, lack of MHC-II expression and no expression of the T-cell costimulatory molecules CD80 and CD86. Thus, it is likely that ESC-HPCs also induce T-cell anergy, which is especially significant because therapy using these cells involves allogenic transplantation. In this study, we conclude that human iPS-HPCs hold enormous promise due to their possible regulatory role on T-cells. Our data reveal for the first time a previously unknown aspect of iPS-HPCs, which is most valuable for both autologous and allogenic transplants.
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